Intech Investment Management LLC Raises Stock Position in Zoetis Inc. $ZTS

Intech Investment Management LLC lifted its stake in shares of Zoetis Inc. (NYSE:ZTS) by 154.2% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 464,141 shares of the company’s stock after acquiring an additional 281,566 shares during the quarter. Zoetis makes up approximately 0.5% of Intech Investment Management LLC’s holdings, making the stock its 23rd biggest holding. Intech Investment Management LLC owned about 0.11% of Zoetis worth $58,398,000 at the end of the most recent reporting period.

Other large investors have also recently modified their holdings of the company. Global Wealth Strategies & Associates purchased a new stake in shares of Zoetis in the fourth quarter valued at approximately $25,000. KERR FINANCIAL PLANNING Corp purchased a new stake in shares of Zoetis in the third quarter valued at approximately $31,000. Lodestone Wealth Management LLC purchased a new stake in shares of Zoetis in the fourth quarter valued at approximately $30,000. Elyxium Wealth LLC purchased a new stake in shares of Zoetis in the fourth quarter valued at approximately $32,000. Finally, Holos Integrated Wealth LLC purchased a new stake in shares of Zoetis in the fourth quarter valued at approximately $32,000. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Key Zoetis News

Here are the key news stories impacting Zoetis this week:

• Positive Sentiment: Zoetis presented at the Stifel Jaws & Paws Conference, which may help reassure investors by giving management a venue to discuss strategy, operations, and the path forward. Zoetis Inc. (ZTS) Presents at Stifel Jaws & Paws Conference 2026 Transcript
• Neutral Sentiment: Argus reiterated a “hold” rating on Zoetis, suggesting analysts are not currently seeing a major catalyst for a near-term rebound. Zoetis had its “hold” rating reaffirmed by Argus
• Negative Sentiment: Multiple law firms announced or expanded class action efforts against Zoetis, with investors alleging harm tied to the period from January 14, 2025 through May 6, 2026; these repeated filings keep legal overhang front and center for shareholders. Rosen Law Firm Urges Zoetis Inc. (NYSE: ZTS) Stockholders to Contact the Firm for Information About Their Rights
• Negative Sentiment: The lawsuits stem from Zoetis’ Q1 results, when the company missed earnings and revenue estimates and cut full-year guidance, raising concerns about growth and execution. Zoetis (ZTS) Securities Fraud Investigation – Levi & Korsinsky

Analysts Set New Price Targets

A number of brokerages recently issued reports on ZTS. Morgan Stanley reiterated an “overweight” rating and issued a $115.00 price target on shares of Zoetis in a report on Friday, May 15th. UBS Group lowered their price target on Zoetis from $130.00 to $99.00 and set a “neutral” rating for the company in a report on Friday, May 8th. Leerink Partners reiterated a “market perform” rating on shares of Zoetis in a report on Tuesday, March 10th. Bank of America boosted their price target on Zoetis from $135.00 to $140.00 and gave the company a “neutral” rating in a report on Friday, February 13th. Finally, Stifel Nicolaus lowered their price target on Zoetis from $105.00 to $95.00 and set a “hold” rating for the company in a report on Friday, May 22nd. Six equities research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $133.92.

Zoetis Stock Down 1.4%

Zoetis stock opened at $78.36 on Friday. The business has a fifty day moving average of $105.08 and a two-hundred day moving average of $117.31. The company has a quick ratio of 1.91, a current ratio of 3.15 and a debt-to-equity ratio of 2.80. The firm has a market cap of $32.85 billion, a P/E ratio of 12.99, a P/E/G ratio of 1.30 and a beta of 0.87. Zoetis Inc. has a twelve month low of $72.38 and a twelve month high of $172.23.

Zoetis (NYSE:ZTS) last posted its earnings results on Thursday, May 7th. The company reported $1.53 earnings per share for the quarter, missing analysts’ consensus estimates of $1.60 by ($0.07). The company had revenue of $2.26 billion for the quarter, compared to analysts’ expectations of $2.30 billion. Zoetis had a return on equity of 66.85% and a net margin of 27.80%.The firm’s quarterly revenue was up 2.9% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.48 EPS. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. On average, analysts forecast that Zoetis Inc. will post 6.88 earnings per share for the current fiscal year.

Zoetis Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 1st. Shareholders of record on Monday, July 20th will be issued a dividend of $0.53 per share. The ex-dividend date is Monday, July 20th. This represents a $2.12 dividend on an annualized basis and a yield of 2.7%. Zoetis’s dividend payout ratio is currently 35.16%.

Insiders Place Their Bets

In other Zoetis news, Director Michael B. Mccallister purchased 3,000 shares of Zoetis stock in a transaction dated Monday, May 11th. The shares were acquired at an average cost of $77.76 per share, with a total value of $233,280.00. Following the completion of the transaction, the director owned 24,524 shares in the company, valued at approximately $1,906,986.24. This trade represents a 13.94% increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Paul Bisaro purchased 2,000 shares of Zoetis stock in a transaction dated Wednesday, May 13th. The shares were acquired at an average cost of $75.88 per share, for a total transaction of $151,760.00. Following the completion of the transaction, the director owned 27,862 shares of the company’s stock, valued at approximately $2,114,168.56. This represents a 7.73% increase in their position. The disclosure for this purchase is available in the SEC filing. Over the last three months, insiders have bought 11,650 shares of company stock valued at $886,384. 0.22% of the stock is currently owned by insiders.

Zoetis Company Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.